Influenza and Developing Vaccines presentation by Yoshihiro Kawaoka, University of Wisconsin Professor of Veterinary Medicine. Introductions by former U.S. Ambassador to Norway Tom Loftus and Jim Leonhart, WBMDA
BOSTON -- Some call it swag, loot, chatchkies or freebies -- but regardless of what they're called, giveaways are essential tools to get people to pay attention to the competing exhibitor messages at BIO '07 in Boston.
As always, stress balls, key chains, chocolate and all the pens and mints you can imagine were among the most common freebies at the event. However, it was the more unusual freebies that most effectively garnered attention from the 20,000 convention goers at the Boston Convention Center.
The belle of the BIO swag ball was a mug resembling a lab beaker given away by a real estate company from California. You could say this one-of-a-kind giveaway drove the scientists mad as a mob of outreached hands surrounded the exhibitor stand at the Tuesday evening BIO reception. This item was so popular that photographers mounted ladders to capture the frenzy.
Another popular freebie at the event included a free psychic reading offered by a staffing company from Massachusetts. Several people (most of them women) lined the walls of this booth many waiting over an hour to have their futures divulged by a young and attractive tarot card reader.
No freebie is more abundant at conventions than candy, but with something sweet available wherever you turn it's refreshing to be offered something healthy. Consistent with their commitment to healthy living, large baskets of apples and oranges attracted many to the booth of a New Jersey health care company specializing in diabetes care.
It's clear that BIO denizens love the "nerdified" version of regular things, especially if they’re free. Some popular items include a deck of biotech playing cards that featured subsectors of biotech on their face and a deck of baseball cards featuring star researchers in Kansas. (And their little dog Toto, too.)
Other collectable items included a mouse pad of the Periodic Chart of Amino Acids, the predictive Eight Ball, decorative pins made from school children in Kenya, pina colada protein shakes, and a pack of juggling balls. Among the most popular items (and a front-runner for the most irritating freebie) was a set of magnetic stones that "sizzled" when they snapped together. Well distributed by a Boston law firm and a couple other exhibitors, by Tuesday evening these rocks could be heard at almost every corner turned in the exhibition hall. Although exhibitors were able to get these in the hands of more than 10 percent of the people present, name recognition was lost as no logos or names were engraved on the items.
In the end, it doesn't matter what you call it, but swag is essential. And it's those unique give aways that command attention and draw people near. That's the stuff we're going to put on our desk, show friends and give our kids as trophies of our travels.
Ever-sensitive that the state squandered its lead in the IT world, Massachusetts officials have unveiled a plan to spend $1.25 billion to help that state stay in the top tier as a place for life science and stem cell research.
The move is in part an attempt to play catch-up with California, which several years ago passed an initiative -- valued at $3 billion -- to support stem cell research.
Tom Still, head of Wisconsin Technology Council, says he's not surprised by the Massachusetts move.
"It just underscores fact that Wisconsin biotech is living in a very competitive world," said Still, who is in Boston for BIO 2007. The international convention, which has drawn more than 20,000 people and more than 200 from the Badger State, ends today.
"States such as Massachusetts, which are already biotech hubs, are investing even more to remain competitive," he said. "We can't afford to lose time or squabble too much because we will be left behind."
Wisconsin plans to spend several hundred million dollars on the Institutes for Discovery on the UW-Madison campus. The first part of the project will break ground next year on the 1300 block of block of University Ave.
This half of the collaborative research facility will cost $150 million, which will be paid for in equal third by the state, WARF and UW-Madison grads John and Tashia Morgridge. The second portion has not yet been funded.
"Clearly, we can't spend $1 billion like Massachusetts or $3 billion like California," Still said. "But we must make sure we get it done. We have unique advantages that we do not want to see eroded."
Still noted that Massachusetts Gov. Deval Patrick, in a column in today's Boston Globe, cited Wisconsin as a reason for his proposed investment.
"Competitor states and foreign nations are investing billions to attract our researchers, institutions and industries. And the University of Wisconsin outspent both Harvard and MIT in research and development," Patrick wrote.
UW-Madison spent $765 million in R&D in fiscal 2004, while Harvard and MIT spent less than $500 million for the same year.
"It shows our efforts are being noticed," Still said. "Massachusetts is now such a big center for biotechnology. It really says something that they feel they need to step up their investment."
Here's some news that biotech researchers and business people should find heartening:
Two different surveys released this week show U.S. voters rate the importance of finding cures to diseases as a top national issue, ahead of the war on terrorism and dealing with illegal immigration. The polls were conducted for the Biotechnology Industry Organization and unveiled at the BIO 2007 convention in Boston.
The surveys were conducted jointly by the nationally recognized Republican and Democratic strategy firms Public Opinion Strategies and Peter D. Hart Research Associates. They compared the views of nationwide voters and senior-level biotechnology industry executives on a number of issues, including health care, the environment, alternative fuels and stem cell research.
Both groups of respondents said they were optimistic that cures to major diseases will be found within the next 10-15 years. According to the survey results, industry leaders and voters share high levels of optimism about the potential for finding cures for serious diseases and, have similar perspectives on the likelihood and importance of finding cures, developing clean technologies to reduce pollution, and creating "green drug factories."
A national telephone survey of 800 registered voters was conducted April 17 to 19, 2007, and a national Internet survey of 252 biotechnology industry leaders was conducted April 11 to 24, 2007.
Tuesday afternoon's live presentations begin at 1 pm, click here to watch.
1:00 Covance Laboratories, Inc. 1:30 Medical College of Wisconsin Research Foundation 2:00 Wisconsin Alumni Research Foundation (WARF) 2:30 Clonex Development, Inc. 3:00 Wisconsin Alumni Research Foundation (WARF)
BOSTON -- So, how much business really takes place at conventions such as the massive BIO '07 meeting in Boston? Aren't these things just a series of parties and gab-fests?
Don't try telling that to Michael Zwick, vice president of business development for Madison-based Neoclone. The annual BIO convention is integral to how the company does business -- with both existing clients and potential customers.
Neoclone produces monoclonal antibodies used in research settings, diagnostics and biotechnology. It has handled about 200 projects for customers worldwide since 1999, and the global nature of the biotech industry means many clients are far removed from Wisconsin.
A prime example is Proteome Systems in Australia, which has been involved in 33 projects with Neoclone over time. Zwick said both firms use the annual BIO convention as a meeting place to discuss their work, which currently revolves around production of biological reagents for testing rapid, non-invasive tuberculosis tests used in developing nations.
While there are shipments of materials between Australia and Madison on a regular basis, Zwick explained, Neoclone executives have yet to visit "down under" and Proteome execs have yet to come to Wisconsin. But that doesn't mean they don't find other ways to meet -- and the annual BIO convention is a natural convener.
"It's neat to think they would work with us," Zwick said. "Obviously, they could choose someone a lot closer."
Zwick said Neoclone also uses BIO's "Partnering Forum" to meet with companies that may have an interest in their work. He described it as a "speed dating" system that often leads to surprising contacts. This year, for example, industry giant Genzyme sought out a meeting with Neoclone.
"We have no free time here except for evenings," said Zwick, who was joined in Boston by CEO Deven McGlenn. "If nothing else, this is a great way to meet with existing clients -- and a valuable forum to meet potential new customers."
BOSTON -- Gov. Jim Doyle is a realist when he talks about Wisconsin's standing in the biotech world. He doesn't pretend the state is on a par with Boston's biotech cluster or San Diego, but he's quick to cite specific areas where the state enjoys a competitive edge.
That message came through clearly Monday during Doyle's stops at the annual BIO convention, where he addressed the Wisconsin delegation, met with Boston-area tech leaders, talked with Boston press and presided over a state reception.
"We live in a very competitive world, and all you need to do to understand that is to take a walk around this convention floor to see what is happening," Doyle told a crowd that gathered at the Wisconsin Pavilion. "Every state is saying it's the best in the country, but we really are a state that stands apart. We do have something to say."
In several formats, Doyle talked about the history of innovation in Wisconsin life sciences, breakthroughs in human embryonic stem-cell research, the state's commitment to the public-private Institutes for Discovery, and a growing number of companies that have grown up in Wisconsin or, in some cases, relocated or expanded there.
Doyle also cited Wisconsin's expertise in bio-based energy, which may emerge as a sustainable alternative to petroleum-based fuels. In addition, he urged Wisconsin business leaders to support initiatives to strengthen the state's education system.
The governor was joined at two presentations by one of UW-Madison's rising stars, Professor Yoshihiro Kawaoka, a leading expert on bird flu and isolation of that killer virus.
In an interview with Boston Business Leader editor George Donnelly, Doyle was asked if he was afraid that Wisconsin could lose some of its up-and-coming biotech companies to states or countries with "open checkbook" recruitment policies. That's an emerging problem even in high-tech havens such as Boston, which must compete with places that offer lower costs of living, reduced barriers to research, tax incentives and cheaper land.
Doyle said the Wisconsin experience thus far has been the opposite, with larger companies (EMD-Merck, Abbott Labs, Genzyme, SAFC and Invitrogen) establishing or growing a presence. He noted that more companies are discovering "there is a vast middle part of the country," and that Wisconsin has natural advantages beyond its research base.
Doyle continued with meetings through Tuesday, when he was scheduled to return to Wisconsin.
Wisconsin last year received another reminder of what its rapidly growing biotechnology industry faces as it seeks to become a new force in the commercial world of science.
At last year's BIO 2006, a gathering of the world's biotechnology industy, there were more than 1,700 exhibitors from 43 states and 36 nations seeking the attention of venture capitialists, angel investors, universities and firms looking to grow or seek partners.
This year, the numbers at BIO 2007 look even larger with more than 25,000 people crowded into Boston's cavernous Convention and Exhibition Center.
The question for Gov. Jim Doyle, his Department of Commerce, the University of Wisconsin System and the state's rapidly growing biotechnology industry is how can Wisconsin rise above the roar of the crowd and make itself known?
There are easily three times more journalists and media representatives here than there are daily newspapers in Wisconsin (the media center lost count). Looking at the world from those journalists' perpective, most states are claiming they are leaders of some sort in biotechnology research and development.
What can Doyle say to set Wisconsin apart?
-- He won a hotly contested 2006 re-election in which human embryonic stem cell research was an issue. Voters in Wisconsin support this research.
-- The Institutes for Discovery, a $150-million interdisciplinary research center, has attracted both public and private financing. Once completed in a few years, the center will become the only center of its kind outside the East and West Coasts. While it will be built with bricks and mortar, the Institutes' foundation stands on more than 100 years of cutting-edge research at UW-Madison.
-- Wisconsin continues to have an edge in human embryonic stem-cell research, leading the world in scientific publications. More than 100 researchers in all disciplines are clustered at UW-Madison.
-- Academic research in Wisconsin, pound for pound, ranks it among the national leaders. A little-known fact: UW-Madison recorded more research spending in 2004 ($764 million) than either the Massachusetts Institute of Technology ($545 million) or Harvard University ($455 million), which lie a stone's throw away from the convention hall.
Raising a state's visibility in this industry will require the collective will of the state's political and industry leaders -- and require it over the long term. With a delegation of 60 sponsors and nearly 200 industry and public representatives here in Boston, Wisconsin is off to a good start.
Flaherty is president of Flaherty & Associates, a public-relations firm based in Madison.
BOSTON -- They sing "Varsity." They call themselves Badgers. And they talk about Bascom Hill as if it's as near by as Beacon Hill.
They're members of the Wisconsin Alumni Association's Boston-area chapter, a group that held a Founders' Day Celebration reception Sunday night at a restaurant overlooking Boston Harbor. The reception was timed to correspond with the start of the 2007 Biotechnology Industrial Organization convention, a gathering of 20,000 techies and friends from around the world.
About 150 UW-Madison grads braved the traffic around the Boston Convention Center to hear UW-Madison professor Alta Charo discuss bioethics, to mingle and to hear the latest news from Madison.
"We've got a very active chapter here," said Jeff Wendorf, vice president of programs and outreach for the WAA, which can reach about 300,000 UW graduates worldwide. "They're always ready to pitch in, either for the university or their community."
The Boston area chapter, which has members who live from New Hampshire to Rhode Island, is 5,000 strong. That's the seventh largest chapter outside of Wisconsin, behind only Chicago, the Twin Cities, New York, San Francisco, Washington, D.C., and Los Angeles/Orange County. There are 70 WAA chapters in the United States and dozens abroad.
In Boston, Wendorf explained, the chapter helps identify students who may want to attend UW-Madison, hosts community send-offs and generally fosters connections with the university.
It's also a gateway for UW-Madison grads who move into the Boston area and want to network with others.
"If you're new to an area, it's a way to connect with other UW alums," Wendorf said.
Among the attendees at Sunday's event were UW Regent and former U.S. ambassador Tom Loftus, who is in Boston attending the BIO '07 convention. UW-Madison Office of Corporate Relations director Charles Hoslet, as well as OCR staffer Allen Dines and Brad Rikker were also present. A portion of the event was sponsored by the Greater Madison Convention and Visitor Bureau, which was represented by Kristi Thering-Tuschen and Ann Shea.
Biotech startup Stemina Biomarker Discovery, Inc. has received exclusive license to Dr. Gabriela Cezar's pioneering stem cell-based technology created at the UW-Madison, it was announced Saturday. The technology uses human embryonic stem cells and metabolomics to detect the potentially toxic effect of drugs in early preclinical stages. The company will present its work at beginning Sunday at BIO international convention in Boston.
According to Stemina CEO Elizabeth Donley Stemina's platform technology utilizes HES cells and derived cell types such as neural cells for drug screening, drug development and diagnostic tool development.
Stemina's goal is to find "biomarkers"-- small molecules secreted in response to drug or disease to be used as a future indicator of a drug's toxicity or to diagnose disease. Stemina's technology uses HES cells instead of lab animals to identify biomarkers involved in human drug toxicity response.
This technology provides an opportunity to look for drug candidates in an all-human cell system. As a result, preclinical drug trials could become more efficient at identifying drugs that have toxic effects earlier in the preclinical pathway, offering pharmaceutical companies an opportunity to develop analogs without toxic effects.
The company's work could also reduce the costs of drug development and lower the need for controversial animal testing.
Cezar, the company's chief scientific officer, developed the technology as a faculty member at UW-Madison. The Wisconsin Alumni Research Foundation (WARF) has licensed Stemina her work as well as the appropriate licenses to the WARF's extensive HES cell patent portfolio based on the work of UW-Madison professor and stem cell researcher Dr. James Thomson.
Founded in 1925, WARF, a nonprofit foundation, bridges the gap between academia and industry by licensing technology from the University to industry which turns university research into real products. The license income then returns to the university to fund future research.
Donley says Stemina also received an exclusive license to a patent covering Dr. Cezar's work in biomarkers of radiation sensitivity in cancers of the brain and spinal cord. Stemina will continue its work in oncology to identify biomarkers of radiation sensitivity in other types of cancers as diagnostic tool to be used in treatment planning.
With the WARF licenses finalized, Donley is looking to introducing Stemina's technology to potential collaborators at BIO international convention.
"Stemina hopes to meet with many of its potential customers and collaborators, especially those international companies which will be there," Donley said. The company will be located in the Wisconsin Pavilion at BIO and Donley will participate in several panels and presentations on behalf of Stemina while in Boston.
Dylewski is a student in the UW-Madison Department of Life Sciences. ###
BOSTON -- At last year's Biotechnology Industry Organization convention in Chicago, it wasn't intimidating for Wisconsin to be strutting its high-tech stuff. While Chicago is a business leader in almost every sense of the word, it's not well known for its biotech. Pharmaceutical companies, yes; biotech firms, not really.
That's not the case in Boston, a place so hopped up on biotech research, investors and boom times companies that the historic "Beantown" nickname has given way to "Genetown."
The 2007 BIO convention is being held in a city that can get a bit snooty about its wealth of research institutions, venture capitalists and biotech companies -- and rightly so. Outside of California, which is the nation's leader in virtually all things tech, Massachusetts is generally acknowledged as the strong No. 2.
So, what's a mid-sized state from the Midwest to do while standing in the shadow of the Giants from Genetown? Thump its chest, of course. Some quick comparisons:
Academic research: Everyone knows about Harvard and the Massachusetts Institute of Technology, two of the nation's finest research centers. But guess which university outspends them both in research and development? In 2004, UW-Madison recorded $764 million in R&D spending, according to the National Science Foundation, compared to $543 million at MIT and $455 million at Harvard. Of course, other institutions in the Boston area such as Boston University ($241 million), the University of Massachusetts ($169 million) and Tufts ($126 million) add to that region's critical mass. Still, if you throw in the Medical College of Wisconsin ($130 million) and other Wisconsin academic institutions (at least $75 million), there's no need for R&D envy.
Tech transfer: The Wisconsin Alumni Research Foundation is the oldest academic tech-transfer organization in the county. It handles 300-plus disclosures per year from professors and researchers. Over time, WARF has received 1,605 patents. It holds 930 active patents, of which 101 were awarded in 2006 and 74 in 2005. License revenue ranks WARF among the nation's top five. Even in Boston, WARF is seen as a model.
Talent production: Recent research by the Wall Street Journal, Bloomberg Markets magazine and executive search firm SpencerStuart shows the UW-Madison has produced the leading number of graduates who are CEOs of major public companies -- more than Harvard in the Fortune 500 and tying Harvard in the S&P 500.
Capital investments: MIT's Whitehead Institute for Biomedical Research is world-renowned, and Harvard University topped the Milken Institute's ratings list in 2006 for biotech research publications. Both are adept at moving from ideas to market. But Wisconsin is moving up in the rear-view mirror. The first phase of the Institutes for Discovery, a UW-Madison facility that will serve as a hub for interdisciplinary research, will cost $150 million. The UW-Milwaukee is planning two quadruple its research and invest $143 million in its infrastructure. The Marshfield Clinic Research Foundation just dedicated its $40 million Laird Center, and the Medical College of Wisconsin continues to add research capacity.
Companies: There are 300-plus biotech companies in the Boston area, including world leaders such as Genzyme. Wisconsin has more than 100 biotech firms, some 60-plus in Dane County alone.
Human embryonic stem cell research: More than 100 researchers are engaged in stem-cell work at the UW-Madison, where Dr. James Thomson was the first in the world to isolate human embryonic stem cells and keep them in an unchanged state. Researchers at Harvard are known for their stem-cell work, as well, but they seem to spend an inordinate amount of time worrying about Wisconsin's patents in the field.
There's no denying the biotech leadership of Boston, but Wisconsin can hold its own in convention floor chats about which states are worthy of the trip to "Genetown." Banned in Boston? Not the biotech delegation from Wisconsin.
-- Still is president of the Wisconsin Technology Council. He is the former associate editor of the Wisconsin State Journal in Madison.
Through cooperation with Madison-based Sonic Foundry, video links to live presentations in Wisconsin's "BioTheater," which is part of the Wisconsin Pavilion at the Boston Convention Center are due to appear on this blog on Monday, Tuesday and Wednesday. Those presentations may also be viewed through http://wan.mediasite.com.
Presentations on Monday, May 7 are due to include Gala Biotech, Platypus Technologies, Stemina Biomarker Discovery, Inc., Caden Biosciences, GE Healthcare, Marshfield Clinic Research Foundation, SAFC, Marshfield Clinic, and Gov. Jim Doyle along with UW-Madison researcher Yoshihiro Kawaoka and former U.S. ambassador Tom Loftus.
Presentations set for Tuesday, May 8 are scheduled to feature Quincy Bioscience, EraGen Biosciences, Gilson Inc. and Mithridion, Covance Laboratories, Medical College of Wisconsin Research Foundation, Wisconsin Alumni Research Foundation, Clonex Development.
Presentations on Wednesday, May 9 are due to feature Wisconsin Biotechnology & Medical Device Association and EPICENTRE Biotechnologies.
Come back to this blog for links to the video presentations.
When BIO 2006 was held in Chicago last April, it was no great surprise that Wisconsin's commercial and academic biotech community wanted to have a major presence at the international conference. It was, in a global sense, just down the road.
And while there will be some drop in attendance at this year's BIO gathering in Boston, the Badger State again will be putting on a good show, officials say. The conference starts Sunday and will run through Thursday.
Last year, Wisconsin spent more than $270,000 -- triple its investment from the 2005 conference in Philadelphia -- to tout its research and business prowess. This time around, the total budget is around $250,000, officials said. But the state did not have the cost of a building a new pavilion this year.
"I believe Chicago was a big success for our state -- on both the research and business side," said Charlie Hoslet, managing director of the UW-Madison Office of Corporate Relations.
"And that's one of the reasons why we are investing a lot in the Boston gathering," said Hoslet. Like last year, the university will again have 400 square feet of the state's 1,600-square-foot pavilion. He said the university will spend between $55,000 and $60,000 this year to tell its story.
Gov. Jim Doyle, UW-Madison avian flu researcher Yoshihiro Kawaoka and UW regent Tom Loftus will speak at the pavilion. In addition, Wisconsin will host a reception at the Boston Harbor Hotel. And, like last year, a Trek bicycle will be given away at the pavilion. In Chicago, more than 3,000 people entered the bike raffle.
Nearly 200 of the state's biotech leaders have indicated they will attend BIO 2007 and 19 companies will deliver talks at the Wisconsin pavilion, up from around a dozen last year, said Jim Leonhart, executive director of the Wisconsin Biotechnology and Medical Device Association.
While the 200 figure is a drop from 250 Wisconsinites who went to the Chicago BIO last year, Leonhart said it is still an impressive number.
"I think a lot of people drove down for a day or two last year," said Leonhart, who noted that Wisconsin has 330 biotech and 170 medical device companies -- an increase of 7 percent from last year.
1st The Wisconsin Alumni Research Foundation is the oldest academic tech-transfer organization in the county. It handles 300-plus disclosures per year from professors and researchers. Over time, WARF has received 1,605 patents. It holds 930 active patents, of which 101 were awarded in 2006 and 74 in 2005. License revenue ranks among the nation's top five.
1st Recent research by the Wall Street Journal, Bloomberg Markets magazine and executive search firm SpencerStuart shows that the University of Wisconsin has produced the leading number of graduates who are CEOs of major public companies -- more than Harvard in the Fortune 500 and tying Harvard in the S&P 500.
4th UW-Madison's rank among public universities in research spending ($799M), placing it ahead of Harvard University and in a class with the Massachusetts Institute of Technology.
Top 25 Where you'll find UW-Madison's College of Agriculture and Life Sciences, School of Veterinary Medicine, School of Business, Department of Computer Sciences and College of Engineering in national rankings.
100 Estimated number of researchers involved in human embryonic stem cell research at UW-Madison, an effort headed by Dr. James Thomson.
22,000 Workers in biotech or medical device companies statewide. In Dane County alone (Madison area), there are 510 high-tech businesses of all descriptions.
$25-$30 million Total value of sponsored research at the Marshfield Clinic, which is among the largest private clinics in the nation. It hosts one of the largest "personalized medicine" projects outside Iceland.
$130 million Research conducted by the Medical College of Wisconsin conducts in research each year, placing it among the nation's top 100 institutions.
$150 million In private and public investments made in the Institutes for Discovery, a UW-Madison facility that will serve as a hub for interdisciplinary research.
$1 billion Total academic R&D spending in Wisconsin per year. Other research leaders include Marquette University, the UW-Milwaukee and other UW System campuses.
Tom Still is president of the Wisconsin Technology Council and its membership subsidiary, the Wisconsin Innovation Network, which has chapters in Madison, Milwaukee, Northeast Wisconsin, Central Wisconsin, the Chippewa Valley and the Lake Superior region. The Tech Council is the independent, non-profit science and technology advisor to the governor and the Legislature. Its work centers on policy formation, economic development and network creation.
Still has served on the Industrial Advisory Board to the UW-Madison College of Engineering, the Board of Visitors of the UW Extension, the Madison Economic Development Commission, the Dane County Economic Strategies Group, the Governor's Economic Growth Council, the Diabetes and Wellness Foundation and other civic and business groups. He is the former associate editor of the Wisconsin State Journal in Madison and continues to write a weekly column, "Inside Wisconsin." He recently co-authored "Hands-On Environmentalism," published by Encounter Books, New York. Still is a lecturer in the UW-Madison Department of Life Sciences Communication.
Ryann Petit-Frere is the communications specialist for the Wisconsin Technology Council. Along with developing the Tech Council's marketing strategy and promotions, Petit-Frere coordinates Wisconsin Edge, a traveling public awareness stem cell initiative
Petit-Frere spent three years in a lab setting as a Hematology lab technician. Interested in the effective communication of science, she earned her Bachelors of Science degrees in Biology and Life Science Communications from the University of Wisconsin -- Madison.
Joe Kremer is the director of the Wisconsin Angel Network (WAN), a public-private initiative launched in January 2005 to fuel the growth of entrepreneurial, early-stage financing throughout Wisconsin.
Kremer is the co-founder and former CFO of Madison-based PowerDesigners LLC, a high-tech power electronics firm. He served as an economic development policy advisor for the Wisconsin State Legislature, worked in the European headquarters' finance departments of Kraft and PepsiCo Restaurants International, and consults for entrepreneurial and non-profit organizations on business and financial strategies.
Kremer, an MBA in Finance, is also a graduate of the University of Wisconsin's Weinert Applied Venture in Entrepreneurship. He earned his bachelor's degree from the University of Wisconsin.
"Wisconsin is a great place to do business because of its quality of life, and its great public schools from kindergarten to Ph.D and the University of Wisconsin System. The university receives more federal research funding than any other public university in the country. It is a national leader in biotechnology and its life science faculty is one of the largest in the country. To bring these advantages to the marketplace, the Wisconsin Alumni Research Foundation (WARF) is ready to help any business gain access to the wealth of discoveries from the University of Wisconsin campuses. WARF is recognized nationally for its ability to work with industry, to transfer technology from the lab bench to the marketplace."
Carl Gulbrandsen Managing Director, Wisconsin Alumni Research Foundation "Wisconsin supports and enhances Promega's key values: continued innovation, customer responsiveness and quality of life.
Close proximity to world-class research institutions, such as the University of Wisconsin and the Medical College of Wisconsin, generates a wealth of creative opportunity. Having neighbors like these, along with other innovative high-tech businesses, fosters collaborations that are critical to keep pace with the needs of our customers worldwide.
Promega is headquartered in Madison, consistently voted one of the country's "most livable cities." Complimented by lakes and natural beauty, with a growing arts district rivaling the best in the Midwest, Madison offers a rich, balanced environment that contributes to attracting and retaining top talent. Combined with the state's top-ten ranking in education and ease of travel, Wisconsin proves a wonderful place to live and work."
Bill Linton President & CEO, Promega Corporation "Researchers at the University of Wisconsin make discoveries across the campus that businesses need to stay competitive and create new products. My discovery of human embryonic stem cells not only has the vast potential to find treatments and cures for the world's most devastating diseases, it also has created a whole new industry. Over the last several years over 30 start-up companies have formed based upon discoveries from the University of Wisconsin faculty members. Employers in Wisconsin will also find graduates who are not only well-trained in the latest technologies, but many also have business knowledge and experience. Wisconsin graduates are ready when you are!"
--James Thomson Developmental Biologist, University of Wisconsin Madison